

Date: November 12, 2020

To
The Department of Corporate Services
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001

Scrip Code: BSE: 526301

Dear Sir,

Sub: Submission of Un-Audited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended 30th September, 2020


In compliance with Regulation 33 & 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find the enclosed Un-Audited Financial Results for the Second Quarter and Half Year ended 30th September, 2020 (Standalone and Consolidated) which have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on November 12, 2020 and also the Limited Review Report furnished by the Statutory Auditors of the Company.

The meeting of the Board of Directors of the Company commenced at 3.00 P.M and concluded at 3.45 P.M.

We request you to please take the above on record.

Thanking you,

Yours faithfully
For Medinova Diagnostic Services Limited



V. Sri Lakshmi
Company Secretary
FCS: 9950

MEDINOVA DIAGNOSTIC SERVICES LIMITED

CIN: L85110TG1993PLC015481

Regd. Office : 7-1-58/A/ FF8 , Flat No. 8, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER, 2020

(Rs. in Lakhs)

Sl. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2020 (Unaudited)	30.06.2020 (Unaudited)	30.09.2019 (Unaudited)	30.09.2020 (Unaudited)	30.09.2019 (Unaudited)	31.03.2020 (Audited)
1	Income:						
	(a) Revenue from operations	436.44	131.96	133.80	568.40	279.62	549.30
	(b) Other Income	5.52	5.88	5.58	11.40	8.72	26.32
	Total Income	441.96	137.84	139.38	579.80	288.34	575.62
2	Expenses						
	(a) Cost of Material Consumed	38.29	13.74	21.93	52.03	45.92	85.55
	(b) Employees benefit Expense	41.75	35.54	47.86	77.29	90.89	178.91
	(c) Testing Fees	204.12	21.39	7.76	225.51	17.41	31.08
	(d) Finance Costs	9.50	9.49	10.49	18.99	21.92	42.36
	(e) Depreciation & Amortisation Expenses	7.86	7.22	10.35	15.08	20.59	41.22
	(f) Other Expenses	62.44	43.45	62.68	105.89	125.61	223.49
	Total Expenses	363.96	130.83	161.07	494.79	322.34	602.61
3	Profit / (Loss) before Exceptional and Extraordinary items and Tax (1-2)	78.00	7.01	(21.69)	85.01	(34.00)	(26.99)
4	Exceptional Items	-	-	-	-	-	-
5	Profit/(Loss) before Extraordinary items and Tax	78.00	7.01	(21.69)	85.01	(34.00)	(26.99)
6	Extraordinary Items	-	-	-	-	-	-
7	Profit / (Loss) before Tax (5-6)	78.00	7.01	(21.69)	85.01	(34.00)	(26.99)
8	Tax Expenses						
	(a) Current Tax	-	-	-	-	-	-
	(b) Deferred Tax (Credit) /Charge	-	-	-	-	-	2.58
	(c) Taxes of earlier years	0.43	-	-	0.43	-	-
9	Profit / (Loss) for the period (7-8)	77.57	7.01	(21.69)	84.58	(34.00)	(29.57)
10	Other Comprehensive income	-	-	-	-	-	(0.27)
11	Total Comprehensive income for the period (9+10)	77.57	7.01	(21.69)	84.58	(34.00)	(29.84)
12	Paid-up Equity Share capital (Face Value Rs 10/- per share)	995.68	995.68	995.68	995.68	995.68	995.68
13	Earnings per Equity Share						
	a) Basic (Rs.)	0.78	0.07	(0.22)	0.85	(0.34)	(0.30)
	b) Diluted (Rs.)	0.78	0.07	(0.22)	0.85	(0.34)	(0.30)

Notes to Standalone Unaudited Financial Results for the Quarter and Half Year Ended 30th September, 2020

1. The unaudited Financial Results of the Company have been prepared in accordance with the Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.

2. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 12th November, 2020. The Statutory Auditors of the Company have carried out limited review of these results and the results are being published in accordance with regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

3. As the Company's business activity falls within a single primary business segment (viz Diagnostic Services) the disclosure requirements of Accounting Standard (AS-108) " Operating Segments" issued by the Institute of Chartered Accountants of India are not applicable.

4. The Company has considered internal and external sources of information up to the date of approval of these financial results in evaluating the possible affects that may result from the pandemic relating to COVID-19 on the carrying amounts of trade and unbilled receivables. The Company has applied prudence in arriving at the estimates and assumptions. The Company is confident about the recoverability of these assets.

5. Previous period Figures have been regrouped/reclassified, as considered necessary, to conform with the current period presentation, wherever applicable.

For MEDINOVA DIAGNOSTICS SERVICES LTD

SUNIL CHANDRA KONDAPALLY
MANAGING DIRECTOR
DIN 01409332

Place: Hyderabad
Date: 12.11.2020



6. Statement of Standalone Assets & Liabilities as at 30th September, 2020

(Rs. in Lakhs)			
SI No.	Particulars	As at 30.09.2020 (Unaudited)	As at 31.03.2020 (Audited)
I	ASSETS		
1	Non Current assets		
	(a) Property plant and equipment	105.23	103.36
	(b) Financial assets		
	(i) Investments	126.82	126.82
	(ii) Trade receivables	19.94	14.39
	(iii) Other financial assets	14.02	14.03
	(c) Deferred Tax Assets (net)	41.17	41.17
	(d) Other Non Current Assets	-	0.43
2	Current assets		
	(a) Inventories	9.63	6.32
	(b) Financial asstes		
	(i) Trade receivables	29.44	30.68
	(ii) Cash and cash equivalents	54.63	6.72
	(iii) Other Bank Balance	22.59	14.53
	(c) Current Tax Assets	35.64	38.13
	(d) Other current assets	4.35	5.57
	TOTAL ASSETS	463.46	402.15
II	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity share capital	995.68	995.68
	(b) Other equity	(1,678.69)	(1,763.26)
2	Liabilities		
A	Non current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	331.93	402.59
	(b) Provisions	22.45	33.54
B	Current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	544.12	484.90
	(iii) Other financial liabilities	149.18	158.70
	(b) Other current liabilities	80.62	77.32
	(c) Provisions	18.17	12.68
	TOTAL EQUITY AND LIABILITIES	463.46	402.15

For MEDINOVA DIAGNOSTICS SERVICES LTD

SUNIL CHANDRA KONDAPALLY
MANAGING DIRECTOR
DIN 01409332

Place: Hyderabad
Date: 12.11.2020



7. Statement of Standalone Cash Flows:

(Rs. in Lakhs)

Particulars	Half Year ended 30.09.2020	Half Year ended 30.09.2019	Year ended 31.03.2020
A. Cash flows from operating activities			
Profit/ (Loss) before tax	85.01	(34.00)	(26.99)
Adjustments to reconcile Profit before tax to net cash flows:			
- Depreciation	15.08	20.59	41.22
- Finance cost on borrowings	17.22	20.84	40.08
- Provision for Employee Benefits	3.66	3.87	7.33
Operating Profit before working capital changes	120.97	11.30	61.64
Changes in working capital:			
Decrease/(Increase) in inventories	(3.31)	(0.61)	0.45
Decrease/(Increase) in trade receivables	(4.31)	(8.09)	(1.59)
Decrease/(Increase) in long-term loans and advances	-	0.30	0.29
Decrease/(Increase) in other current assets	1.22	1.59	(1.98)
Increase/(decrease) in trade payables	59.22	30.05	16.32
Increase/(decrease) in other current liabilities/provisions	(5.96)	(30.82)	(25.42)
Cash generated from Operating Activities	167.83	3.72	49.71
Taxes paid	2.49	(3.61)	(7.02)
Net cash flow from operating activities (A)	170.32	0.11	42.69
B. Cash flows from investing activities			
Purchase Value of fixed assets	(16.94)	-	(0.30)
Deposits placed having original maturities of more than 3 months (Net)	(8.06)	(6.13)	(14.54)
Net cash used in investing activities (B)	(25.00)	(6.13)	(14.84)
C. Cash flows from financing activities			
(Repayment)/Loans from Holding Company	(70.66)	42.66	42.66
Repayment of long-term borrowings	(20.29)	(27.70)	(57.00)
Finance cost paid on borrowings	(6.46)	(6.32)	(12.21)
Net cash used/generated from financing activities (C)	(97.41)	8.64	(26.55)
Net increase in cash and cash equivalent (A+B+C)	47.91	2.62	1.30
Opening balance of cash and cash equivalents	6.71	5.41	5.41
Closing balance of cash and cash equivalents	54.62	8.03	6.71
<i>Cash and cash equivalents comprise :</i>			
Cash in hand	5.61	0.90	0.27
Balances with banks- Current Accounts	49.01	7.13	6.44
Total cash and cash equivalents	54.62	8.03	6.71

For MEDINOVA DIAGNOSTICS SERVICES LTD

SUNIL CHANDRA KONDAPALLY
MANAGING DIRECTOR
DIN 01409332

Place: Hyderabad
Date: 12.11.2020




Independent Auditor's Limited Review Report on the Quarterly & Year to date Unaudited Standalone Financial Results of Medinova Diagnostic Services Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors,
Medinova Diagnostic Services Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Medinova Diagnostic Services Limited ("the company") for the Quarter ended 30th September 2020, and year to date from 01st April 2020 to 30th September 2020 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the Listing Regulations").
2. The Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards and other recognised accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is disclosed, or that it contains any material misstatement.

For Ratnam Dhaveji & Co
Chartered Accountants
Regd No 006677S


C V Ratnam Dhaveji
Partner, M.No 203479
Hyderabad
12.11.2020



UDIN: 20203479 AA AA BP1026.

MEDINOVA DIAGNOSTIC SERVICES LIMITED

CIN: L85110TG1993PLC015481

Regd. Office : 7-1-58/A/ FF8 , Flat No. 8, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2020

(Rs in Lakhs)

Sl. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2020 (Unaudited)	30.06.2020 (Unaudited)	30.09.2019 (Unaudited)	30.09.2020 (Unaudited)	30.09.2019 (Unaudited)	31.03.2020 (Audited)
1	Income:						
	(a) Revenue from operations	465.13	154.24	183.24	619.37	382.05	744.70
	(b) Other Income	0.05	0.40	0.20	0.45	0.31	7.40
	Total Income	465.18	154.64	183.44	619.82	382.36	752.10
2	Expenses						
	(a) Cost of Material Consumed	41.75	16.00	26.09	57.75	53.94	108.84
	(b) Employees benefit Expense	45.56	38.72	51.27	84.28	97.05	191.82
	(c) Testing Fees	204.11	21.39	7.76	225.50	17.41	31.08
	(d) Finance Costs	13.23	13.16	14.89	26.39	31.21	59.37
	(e) Depreciation & Amortisation Expenses	17.80	17.06	23.79	34.86	47.33	95.11
	(f) Other Expenses	83.83	61.37	87.74	145.20	169.01	293.45
	Total Expenses	406.28	167.70	211.54	573.98	415.95	779.67
3	Profit/(Loss) before Exceptional and Extraordinary items and Tax (1-2)	58.90	(13.06)	(28.10)	45.84	(33.59)	(27.57)
4	Exceptional Items	-	-	-	-	-	-
5	Profit/(Loss) before Extraordinary items and Tax (3+4)	58.90	(13.06)	(28.10)	45.84	(33.59)	(27.57)
6	Extraordinary Items	-	-	-	-	-	-
7	Profit/(Loss) before Tax (5-6)	58.90	(13.06)	(28.10)	45.84	(33.59)	(27.57)
8	Tax Expenses						
	(a) Current Tax	-	-	-	-	-	-
	(b) Deferred Tax (Credit) / Charge	-	-	-	-	-	(4.80)
	(c) Taxes of earlier years	0.43	-	-	0.43	-	-
9	Profit/(Loss) for the period (7-8)	58.47	(13.06)	(28.10)	45.41	(33.59)	(22.77)
10	Other Comprehensive Income	-	-	-	-	-	(0.27)
11	Total Comprehensive income for the period (9+10)	58.47	(13.06)	(28.10)	45.41	(33.59)	(23.04)
	Net Profit attributable to:						
	(a) Owners of the Company	67.07	(4.03)	(25.20)	63.04	(33.77)	(25.82)
	(b) Non Controlling Interest	(8.60)	(9.03)	(2.88)	(17.63)	0.19	3.05
	Other Comprehensive Income attributable to:						
	(a) Owners of the Company	-	-	-	-	-	(0.27)
	(b) Non Controlling Interest	-	-	-	-	-	-
	Total Comprehensive Income attributable to:						
	(a) Owners of the Company	67.07	(4.03)	(25.20)	63.04	(33.77)	(26.09)
	(b) Non Controlling Interest	(8.60)	(9.03)	(2.88)	(17.63)	0.19	3.05
12	Paid-up Equity Share capital (Face Value Rs 10/- per share)	995.68	995.68	995.68	995.68	995.68	995.68
13	Earnings per Equity Share						
	a) Basic (Rs.)	0.67	(0.04)	(0.25)	0.63	(0.34)	(0.26)
	b) Diluted (Rs.)	0.67	(0.04)	(0.25)	0.63	(0.34)	(0.26)

Notes to Consolidated Unaudited Financial Results for the Quarter and Half Year Ended 30th September, 2020

1. The Consolidated unaudited Financial Results of the Group have been prepared in accordance with the Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.

2. The above Consolidated unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 12th November, 2020. The Statutory Auditors of the Group have carried out limited review of these results and the results are being published in accordance with regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

3. As the Group's business activity falls within a single primary business segment (viz Diagnostic Services) the disclosure requirements of Accounting Standard (AS-108) "Operating Segments" issued by the Institute of Chartered Accountants of India are not applicable.

4. The Group has considered internal and external sources of information up to the date of approval of these financial results in evaluating the possible effects that may result from the pandemic relating to COVID-19 on the carrying amounts of trade and unbilled receivables. The Group has applied prudence in arriving at the estimates and assumptions. The Group is confident about the recoverability of these assets.

5. Previous period Figures have been regrouped/reclassified, as considered necessary, to conform with the current period presentation, wherever applicable.

For MEDINOVA DIAGNOSTIC SERVICES LTD

SUNIL CHANDRA KONDAPALLY
MANAGING DIRECTOR
DIN 01409332

Place: Hyderabad
Date: 12.11.2020



5. Statement of Consolidated Assets & Liabilities as at 30th September, 2020

SI No.	Particulars	(Rs. in Lakhs)	
		As at 30.09.2020 (Unaudited)	As at 31.03.2020 (Audited)
I	ASSETS		
1	Non Current assets		
	(a) Property plant and equipment	222.45	240.37
	(b) Financial assets		
	(i) Investments	-	-
	(ii) Trade receivables	19.93	14.39
	(iii) Other financial assets	14.03	14.03
	(c) Deferred Tax Assets (net)	26.13	26.13
	(d) Other Non Current Assets	-	0.43
2	Current assets		
	(a) Inventories	11.26	8.10
	(b) Financial asstes		
	(i) Trade receivables	29.11	34.51
	(ii) Cash and cash equivalents	55.21	6.76
	(iii) Other Bank Balance	22.59	14.53
	(c) Current Tax Assets	38.81	40.56
	(d) Other current assets	5.08	6.12
	TOTAL ASSETS	444.60	405.93
II	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity share capital	995.68	995.68
	(b) Other equity	(1,849.83)	(1,912.86)
2	Non Controlling Interest	(36.58)	(18.96)
3	Liabilities		
A	Non current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	331.93	402.59
	(b) Provisions	52.01	61.76
B	Current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	147.08	130.45
	(ii) Trade payables	553.99	496.45
	(iii) Other financial liabilities	149.18	158.70
	(b) Other current liabilities	82.97	79.43
	(c) Provisions	18.17	12.69
	TOTAL EQUITY AND LIABILITIES	444.60	405.93

For MEDINOVA DIAGNOSTICS SERVICES LTD

Place: Hyderabad
Date: 12.11.2020

SUNIL CHANDRA KONDAPALLY
MANAGING DIRECTOR
DIN 01409332



6. Statement of Consolidated Cash Flows:

(Rs. in Lakhs)

Particulars	Half Year ended 30.09.2020 Unaudited	Half Year ended 30.09.2019 Unaudited	Year ended 31.03.2020 Audited
A) Cash flows from operating activities			
Profit / (Loss) before tax	45.84	(33.59)	(27.57)
Adjustments to reconcile Profit before tax to net cash flows:			
- Depreciation	34.86	47.33	95.11
- Loss/ (Profit) on sale of fixed assets	-	-	(0.29)
- Finance cost on borrowings	22.97	28.30	53.37
- Provision for employee benefits	3.66	3.88	7.33
- Interest on Decommissioning Liability	1.34	1.29	2.57
Operating Profit before working capital changes	108.67	47.21	130.52
Changes in working capital:			
Decrease/(Increase) in inventories	(3.15)	(1.17)	1.45
Decrease/(Increase) in trade receivables	(0.15)	(19.31)	1.63
Decrease/(Increase) in long-term loans and advances	-	0.30	0.30
Decrease/(Increase) in other current assets	1.04	1.51	(1.47)
Increase/(decrease) in trade payables	57.54	41.65	25.10
Increase/(decrease) in other current liabilities/provisions	(4.37)	(14.83)	(29.65)
Cash generated from operations	159.58	55.36	127.88
Taxes paid	1.75	(4.18)	(3.44)
Net cash flow from operating activities (A)	161.33	51.18	124.44
B). Cash flows from investing activities			
Purchase of fixed assets	(16.94)	-	(2.29)
Deposits placed having original maturities of more than 3 months (Net)	(8.06)	(6.13)	(14.53)
Proceed from sale of fixed assets	-	-	0.60
Net cash used in investing activities (B)	(25.00)	(6.13)	(16.22)
C). Cash flows from financing activities			
(Repayment)/Loans from Holding Company	(70.66)	42.66	42.66
Repayment of long-term borrowings	(20.29)	(27.70)	(57.00)
Proceeds from short-term borrowings	16.62	(42.44)	(64.86)
Finance cost paid on borrowings	(13.55)	(15.06)	(28.08)
Net cash used/generated from financing activities (C)	(87.88)	(42.54)	(107.28)
Net increase in cash and cash equivalent (A+B+C)	48.45	2.51	0.94
Opening balance of cash and cash equivalents	6.76	5.82	5.82
Closing balance of cash and cash equivalents	55.21	8.33	6.76
<i>Cash and cash equivalents comprise :</i>			
Cash on hand	6.20	1.19	0.31
Balances with banks- Current Accounts	49.01	7.14	6.45
Total cash and cash equivalents	55.21	8.33	6.76

Place: Hyderabad
Date: 12.11.2020



For MEDINOVA DIAGNOSTICS SERVICES LTD

SUNIL CHANDRA KONDAPALLY
MANAGING DIRECTOR
DIN 01409332



Independent Auditor's Limited Review Report on the Quarterly & Year to date Unaudited Consolidated Financial Results of Medinova Diagnostic Services Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors,
Medinova Diagnostic Services Limited**

1. We have reviewed the accompanying statement of unaudited Consolidated financial results of Medinova Diagnostic Services Limited ("the Parent") and its subsidiary LLP (together referred to as the "Group") for the Quarter ended 30th September 2020 and the year to date from 01st April 2020 to 30th September 2020 ("the Statement") being submitted by the parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations).
2. The Statement, which is the responsibility of the Parent's management and approved by the Parents Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matter that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable

4. The Statement includes the results of the following entities:

S.No	Name of the Entity	Nature of Relation
1.	Medinova Diagnostic Services Limited	The Parent
2.	Medinova Millennium MRI Services LLP	The Subsidiary LLP



5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements, prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 as amended with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ratnam Dhaveji & Co
Chartered Accountants
Regd No 006677S

C V Ratnam Dhaveji
C V Ratnam Dhaveji
Partner, M.No 203479
Hyderabad



12.11.2020
UDIN: 20203479 AAAA BQ 4645